Toxicity prediction in radiotherapy for pelvic cancers, assessing the added value of biological parameters to RT treatment planning variables

Toxicity prediction in radiotherapy for pelvic cancers, assessing the added value of biological parameters to RT treatment planning variables - StopRTox

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55564

Enrollment

200

Registered

2018-07-24

Start date

2018-09-07

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pelvic cancers pelvic tumors

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -Histologically confirmed urogenital carcinoma (i.e. cervix, uterus, vagina, vulva, prostate, bladder) or rectal cancer -Newly diagnosed patients who are to receive 'radical' EBRT or already treated patients, 6 to 24 months after curative EBRT. (Both patients receiving primary RT and those receiving adjuvant (post-operative) RT are eligible for this study) -Proficient in Dutch -Written informed consent prior to participation

Exclusion criteria

Exclusion criteria: -Radiotherapy for recurrent disease -Patients with prostate cancer who had prostatectomy or iodine-125 brachytherapy -Psychosocial or somatic disorders in the medical history, limiting the possibilities for adequate follow-up

Design outcomes

Primary

Measure	Time frame
Late radiation toxicity	—

Countries

Netherlands

Outcome results